Cantor Fitzgerald cautious on Caribou Biosciences, starts a Neutral

As previously reported, Cantor Fitzgerald initiated coverage of Caribou Biosciences with a Neutral rating and no price target. Caribou is developing “off the shelf” allogeneic CAR-T therapies, including lead programs CB-010 for B-cell non-Hodgkin’s lymphoma, or B-NHL, and CB-011 for multiple myeloma, or MM, the analyst noted. While saying that early clinical data from CB-010 has “shown promise,” the firm chooses to remain on the sidelines for more mature data from CB-010 and a clear clinical path for development in second-line LBCL, the analyst tells investors.